Prolia® Postmarketing Active Safety Surveillance Program for Soliciting Adverse Events of Special Interest in the United States (PASP-EMR Program)

First published 16/01/2017

Last updated 22/02/2024

EU PAS number:

EUPAS17198

Study

Finalised

Documents

Study protocol

Initial protocol

20090601Protocol Amend 2 2016 Fully Redacted

English (555.62 KB - PDF) View document

Updated protocol

20090601Protocol Amend 2 2016-06-23

First published: 22/02/2024

English (2.84 MB - PDF) View document

Study results

denosumab 20090601 Observational Final Analysis Abstract

English (216.32 KB - PDF) View document

Study report

Other information

Secondary tabs